Last updated: February 19, 2025
Sponsor: Universidad Europea de Madrid
Overall Status: Active - Recruiting
Phase
4
Condition
Carpal Tunnel Syndrome
Treatment
Median nerve neural mobilization and oral gabapentin
Gabapentin 300mg
Clinical Study ID
NCT06778798
CE0072015-02-06
Ages 18-70 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Participants must be medically diagnosed with unilateral carpal tunnel syndrome (with confirmative electrodiagnostic findings).
Full understanding of written and spoken Spanish (language).
Participants must freely consent to participate.
The presence of positive Phalen an Tinel sings.
The presence of carpal tunnel syndrome signs and symptoms
Exclusion
Exclusion Criteria:
- The lack to meet inclusion criterions, the presence of cognitive impairment, tumors,cancer, recent (affected) upper limb surgery or trauma, pregnancy, kinesiophobia,deformities of the (affected) upper limb, recent skin injuries or infections (in theaffected upper limb), autoimmune inflammatory conditions or flu type symptoms,allergy to gabapentin, allergy to ibuprofen arginine, and also: participants mustnot be (during the present investigation) under any type of pain reducing treatment (conservative, homeopathic, invasive or not invasive)
Study Design
Total Participants: 21
Treatment Group(s): 2
Primary Treatment: Median nerve neural mobilization and oral gabapentin
Phase: 4
Study Start date:
February 19, 2025
Estimated Completion Date:
March 31, 2025
Study Description
Connect with a study center
Ciudad Hospitalaria Enrique Tejera
Valencia, Carabobo 02001
VenezuelaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.